secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268146
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX posts positive Phase 2 results for canvuparatide; Q3 net loss $21.6M; cash $391.7M
--------------------------------------------------------------------------------

- Q3 2025 net loss $21.6M vs $18.1M YoY; cash and equivalents $391.7M (includes $200M offering proceeds) funding into 2029.
- Positive Phase 2 topline: 63% of canvuparatide-treated patients met composite endpoint at 12 weeks; 79% at 6 months in open-label extension.
- Dosed first participant in Phase 1 trial of MBX 4291 (GLP-1/GIP co-agonist) for obesity; results from MAD portion expected Q4 2026.
- Dosed first patient in Phase 2a trial of imapextide for post-bariatric hypoglycemia; results expected Q2 2026.
- Director changes: James Cornelius resigned Oct 31; Steven Hoerter appointed executive chairman effective Nov 6, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/0001193125-25-268146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/mbx-20251031.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer